Adello is a privately held, U.S.-based biotechnology company headquartered in Piscataway, NJ. The company's aim is to provide high-quality, affordable biosimilars to patients worldwide. Driven by a team of highly skilled industry veterans, Adello is advancing a pipeline of complex proteins and monoclonal antibodies with lead candidates in oncology and immunology.
Tarsadia's investor group partnered with Adello's predecessor shareholders in early 2012, by forming a new company and providing the new company with growth capital to continue its product development and commercialization initiatives. Tarsadia continues to provide stategic planning and growth-oriented advice.